Sprouty keeps bowel kinases regular in colon cancer, while miR-21 targets sprouty

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 122-124

  Frey, Mark R ^a   Carraro, Gianni ^a   Batra, Raj K ^b   Polk, D Brent ^a   Warburton, David ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Colon cancer; Growth factors; MAPK signaling; MicroRNA; Receptor tyrosine kinases; Sprouty proteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SOS PROTEIN; SPROUTY PROTEIN; TUMOR NECROSIS FACTOR;

ADENOCARCINOMA; CANCER CELL; CELL MIGRATION; COLON CANCER; DOWN REGULATION; ENTERITIS; ENZYME ACTIVITY; HUMAN; INTESTINE; LUNG NON SMALL CELL CANCER; NOTE; UPREGULATION;

ANIMALS; COLONIC NEOPLASMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICRORNAS;

EID: 78751517914     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.14176     Document Type: Note

References (26)

1. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5:44-60.
2. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010; 16:196-201.
3. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009; 20:851-5.
4. Feng YH, Wu CL, Tsao CJ, Lu PJ, Yeh KT, Uen YH, et al. Deregulated expression of sprouty2 and microrna-21 in human colon cancer: correlation with clinical stage of disease. Cancer Biol Ther 2010.
5. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998; 92:253-63.
6. Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell 1999; 96:655-65.
7. Kramer S, Okabe M, Hacohen N, Krasnow MA, Hiromi Y. Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. Development 1999; 126:2515-25.
8. Tefft JD, Lee M, Smith S, Leinwand M, Zhao J, Bringas P Jr, et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol 1999; 9:219-22.
9. Edwin F, Anderson K, Ying C, Patel TB. Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol 2009; 76:679-91.
10. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004; 64:6127-36.
11. Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, et al. Downregulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 2007; 5:509-20.
12. McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005; 24:2166-74.
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61.
14. Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19:3272-82
15. Tefft D, Lee M, Smith S, Crowe DL, Bellusci S, Warburton D. mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins. Am J Physiol Lung Cell Mol Physiol 2002; 283:700-6.
16. von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, et al. Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol 2009; 11:1458-64.
17. Kaiser GC, Yan F, Polk DB. Conversion of TNFalpha from antiproliferative to proliferative ligand in mouse intestinal epithelial cells by regulating mitogen-activated protein kinase. Exp Cell Res 1999; 249:349-58.
18. Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A. Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation. J Biol Chem 2001; 276:36804-8.
19. Wong ES, Fong CW, Lim J, Yusoff P, Low BC, Langdon WY, et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J 2002; 21:4796-808.
20. Frey MR, Dise RS, Edelblum KL, Polk DB. p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 2006; 25:5683-92.
21. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar- Sagi D. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr Biol 2003; 13:308-14.
22. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010; 29:5241-53.
23. Barbachano A, Ordonez-Moran P, Garcia JM, Sanchez A, Pereira F, Larriba MJ, et al. Sprouty-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 2010; 29:4800-13.
24. Feng YH, Tsao CJ, Wu CL, Chang JG, Lu PJ, Yeh KT, et al. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci 2010; 101:2033-8.
25. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010; 17:1168-76.
26. Ding W, Warburton D. Downregulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factor-alpha. Biochem Biophys Res Commun 2008; 375:460-4.